Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Cancer J. 2010 May-Jun;16(3):226-34. doi: 10.1097/PPO.0b013e3181e07670.
Treatment of colorectal cancer (CRC) with conventional anticancer treatments has clear benefits in both adjuvant and metastatic settings; however, there are undeniable limitations both in terms of efficacy and toxicity. Molecular targeted therapies have emerged as a new generation of molecules aiming to increase anticancer activity while minimizing side effects. A further desirable attribute is the capacity to be combined with chemotherapy or radiotherapy. Epidermal growth factor receptor inhibitors have emerged to impact outcomes of cancer patients and gain routine clinical use. Cetuximab and panitumumab are the 2 most advanced such compounds. Both have achieved regulatory approval for metastatic CRC. This topic review will focus on the molecular basis and the mechanisms of action of epidermal growth factor receptor inhibitors, the clinical trials in this field and future trends of such compounds in CRC.
采用常规抗癌疗法治疗结直肠癌（CRC）在辅助和转移治疗中均具有明确的益处；然而，无论在疗效还是毒性方面，都存在不可否认的局限性。分子靶向治疗作为新一代分子出现，旨在提高抗癌活性，同时最小化副作用。另一个理想的属性是能够与化疗或放疗联合使用。表皮生长因子受体抑制剂已被证明可影响癌症患者的治疗效果并获得常规临床应用。西妥昔单抗和帕尼单抗是两种最先进的此类化合物。两者均已获得转移性 CRC 的监管批准。本专题综述将重点介绍表皮生长因子受体抑制剂的分子基础和作用机制、该领域的临床试验以及此类化合物在 CRC 中的未来趋势。
